GeoVax Labs, Inc. (NASDAQ:GOVX) Given Average Recommendation of “Buy” by Analysts

Shares of GeoVax Labs, Inc. (NASDAQ:GOVX) have received an average recommendation of “Buy” from the seven research firms that are presently covering the firm, MarketBeat.com reports. Five investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $14.20.

Separately, D. Boral Capital reaffirmed a “buy” rating and set a $18.00 price target on shares of GeoVax Labs in a research report on Thursday, February 27th.

Institutional Investors Weigh In On GeoVax Labs

Several institutional investors have recently made changes to their positions in the stock. Virtu Financial LLC bought a new stake in shares of GeoVax Labs during the 3rd quarter valued at $97,000. Geode Capital Management LLC grew its holdings in GeoVax Labs by 59.0% during the 4th quarter. Geode Capital Management LLC now owns 90,139 shares of the company’s stock valued at $223,000 after buying an additional 33,440 shares in the last quarter. Northern Trust Corp purchased a new stake in shares of GeoVax Labs in the fourth quarter worth about $29,000. Finally, Citadel Advisors LLC purchased a new stake in shares of GeoVax Labs in the fourth quarter worth about $104,000. Hedge funds and other institutional investors own 6.09% of the company’s stock.

GeoVax Labs Stock Performance

GeoVax Labs stock opened at $1.54 on Friday. The business’s 50 day simple moving average is $1.85 and its 200 day simple moving average is $2.33. GeoVax Labs has a 12 month low of $1.09 and a 12 month high of $11.18.

GeoVax Labs Company Profile

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.